Medindia LOGIN REGISTER
Medindia
Advertisement

Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody

Friday, October 3, 2008 General News
Advertisement
DALLAS, Oct. 2 Access Pharmaceuticals, Inc.(OTC Bulletin Board: ACCP) presented data this week from preclinical studieson Angiolix showing that by blocking lactadherin, Angiolix has both ananti-angiogenic effect as well as a direct anti-proliferative effect on tumorsthemselves. In preclinical models of human breast cancer (MX-1), Angiolix hada significant anti-cancer effect in vivo; this effect was enhanced whenAngiolix was given in combination with conventional chemotherapy for breastcancer. The studies were conducted at Imperial College London and presentedat the International Conference titled "Realizing the Commercial Potential ofTherapeutic Antibodies," held in London, UK.
Advertisement

"We are delighted with these results which demonstrate the substantialanti-cancer effect of Angiolix, which we feel is comparable to Avastin yetachieved through a different and potentially complementary mechanism ofaction," stated Jeffrey B. Davis, President & CEO. "As stated previously,Access is actively seeking potential partners for the further clinicaldevelopment of Angiolix."
Advertisement

"Angiolix is highly tumor specific," continued Agamemnon Epenetos, ChiefScientific Officer, Europe, "because the target lactadherin is primarily foundin tumors and not in normal tissues. Other targets, such as VEGF, are presentin many normal tissues; the blocking of VEGF may contribute to side effectssuch as high blood pressure and bleeding episodes, for example. Angiolixappears to be a more tumor selective anti-angiogenesis monoclonal antibody,with the benefit of having anti-proliferative activity."

Access is continuing to conduct pre-clinical studies at Imperial CollegeLondon to more fully define the safety and efficacy profile of Angiolix.

About Angiolix:

Angiolix is a novel humanized monoclonal antibody which has considerablepotential for the treatment of cancer through its affinity for a novel target,lactadherin. Lactadherin is an extracellular matrix protein that is releasedby numerous types of tumor cells, including most breast cancers, ovariancancers and prostate cancer. Lactadherin has a critical role in promoting thegrowth of new blood vessels to support tumor growth through the activation ofVEGF-mediated angiogenesis. The target lactadherin and Angiolix are supportedand protected by granted patents.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company thatdevelops and commercializes propriety products for the treatment andsupportive care of cancer patients. Access' products include ProLindac(TM),currently in Phase 2 clinical testing of patients with ovarian cancer, andMuGard(TM) for the management of patients with mucositis. The company alsohas other advanced drug delivery technologies including Cobalamin(TM)-mediatedtargeted delivery and oral drug delivery, its proprietary nanopolymer deliverytechnology based on the natural vitamin B12 uptake mechanism; Angiolix(R), ahumanized monoclonal antibody which acts as an anti-angiogenesis factor and istargeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activatedin the hypoxic zones of solid tumors to kill cancer cells; Alchemix, achemotherapeutic agent that combines multiple modes of action to overcome drugresistance. Access is also developing Phenylbutyrate ("PB"), an HDACinhibitor and differentiating agent currently a Phase 2 clinical candidate.For additional information on Access Pharmaceuticals, please visit our websiteat http://www.accesspharma.com.

This press release contains certain statements that are forward-lookingwithin the meaning of Section 27a of the Securities Act of 1933, as amended,and that involve risks and uncertainties. These statements include thoserelating to: our ability to close the financing transaction, early resultsfrom our clinical trial, Access' plans to continue and initiate clinicaltrials, the value of its products in the market, its ability to achieveclinical and commercial success and its ability to successfully developmarketed products. These statements are subject to numerous risks, includingbut not limited to Access' need to obtain additional financing in order tocontinue the clinical trial and operations and to the risks detailed inAccess' Annual Reports on Form 10-K and other reports filed by Access with theSecurities and Exchange Commission.

SOURCE Access Pharmaceuticals, Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close